Meddenovo Drug Design

Founded in 2021 and based in Lyon, France, Meddenovo Drug Design operates as a provider of drugs using artificial intelligence technologies and molecular modeling. Ilke Ugur Marion (CEO) and Antoine MARION (CTO) are the co-founders of the company. In July 2024, ACT Venture Partners led EUR 1 million in pre-seed funding for Meddenovo Drug Design. The company specializing in accelerating pharmaceutical research and development using advanced computational biochemistry techniques.

The firm focuses on rational drug design, particularly for cyclic peptides. Meddenovo aims to increase the efficiency of drug discovery by utilizing AI-supported tools, with the potential to reduce drug development costs by up to 30%. The company offers a range of services, including in silico testing of drug candidates, de novo drug design, and the generation of peptide databases tailored to specific therapeutic targets. The firm’s technology platform combines AI and physical computational approaches to support drug hunters in designing novel drug candidates.

It integrates a comprehensive database of cyclic peptide-like medicines, offering unique software solutions for the development of peptide-based therapeutics. The organization plans to use the July 2024 funding to boost its AI-driven platforms, quicken research and development, and increase the company's clientele and alliances.